Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

Presentation

Efficacy and Safety of Apixaban Following Cardioversion for A-fib: ARISTOTLE Insights

Presenter: Greg Flaker

November 14, 2013

Presentation

High Sensitivity Troponin T and Risk Stratification in Patients with A-fib on Apixaban or Warfarin

Presenter: Ziad Hijazi

October 02, 2013

Presentation ESC 2013

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Presenter: Alvaro Avezum

September 03, 2013

Presentation

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

Presenter: David Garcia

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Presenter: Giancarlo Agnelli

July 02, 2013

Presentation

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

Presenter: Sana M. Al-Khatib

May 06, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Presenter: Greg C. Flaker

October 09, 2012

Presentation

Efficacy and Safety of Apixaban vs. Warfarin Based on Patient Risk of Stroke and Bleeding in A-fib

Presenter: Renato D. Lopes

October 03, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

Presentation

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Presenter: Corey S. Miller

May 03, 2012

Presentation

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Presenter: Hans-Christoph Diener

March 08, 2012

Presentation

Apixaban frente a Aspirina en Pacientes con Fibrilación Auricular y Antecedentes de ACV o AIT

Presenter: Hans-Christoph Diener

March 08, 2012

Advertisement

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Efficacy and Safety of Apixaban Following Cardioversion for A-fib: ARISTOTLE Insights

High Sensitivity Troponin T and Risk Stratification in Patients with A-fib on Apixaban or Warfarin

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Efficacy and Safety of Apixaban vs. Warfarin Based on Patient Risk of Stroke and Bleeding in A-fib

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) vs. Warfarin in Patients with A-fib

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Apixaban frente a Aspirina en Pacientes con Fibrilación Auricular y Antecedentes de ACV o AIT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content